Brief: Cullinan Oncology Announces FDA Clearance Of Investigational New Drug Application For CLN-619, For Relapsed/Refractory Multiple Myeloma

Cullinan Therapeutics

01/03/2024 12:08

March 1 (Reuters) - Cullinan Oncology Inc  CGEM.O :
    * CULLINAN ONCOLOGY ANNOUNCES U.S. FDA CLEARANCE OF
INVESTIGATIONAL NEW DRUG APPLICATION FOR NOVEL MICA/B ANTIBODY,
CLN-619, FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    * CULLINAN ONCOLOGY INC - WILL INITIATE PHASE 1 STUDY OF
CLN-619
FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Source text for Eikon:  ID:nGNX4hNmng 
Further company coverage:  CGEM.O 

 ((Reuters.Briefs@thomsonreuters.com;))